# EDGAR Filing Document

**Accession Number:** 0001506983
**File Stem:** 0001641172-25-015194
**Filing Date:** 2025-6
**Character Count:** 14064
**Document Hash:** 3e4b7a32e5448a8f31f43255bdd56d8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015194.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001641172-25-015194

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Glucotrack, Inc.
- **CENTRAL INDEX KEY:** 0001506983
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980668934
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41141
- **FILM NUMBER:** 251048716

**BUSINESS ADDRESS:**
- **STREET 1:** 301 RT 17 NORTH
- **STREET 2:** SUITE 800
- **CITY:** RUTHERFORD
- **STATE:** NJ
- **ZIP:** 07070
- **BUSINESS PHONE:** 972 (8) 675-7878

**MAIL ADDRESS:**
- **STREET 1:** 301 RT 17 NORTH
- **STREET 2:** SUITE 800
- **CITY:** RUTHERFORD
- **STATE:** NJ
- **ZIP:** 07070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GlucoTrack, Inc.
- **DATE OF NAME CHANGE:** 20220328

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integrity Applications, Inc.
- **DATE OF NAME CHANGE:** 20101203

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 13, 2025

**GLUCOTRACK, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-41141</u> <u>98-0668934</u> <br> (State or Other Jurisdiction (Commission (IRS Employer <br> of Incorporation) File Number) Identification No.)

<u>301 Rte 17 North, Ste. 800, Rutherford, NJ</u> <u>07070</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **GCTK** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

 

Glucotrack, Inc., a Delaware corporation (the "Company"), filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Certificate of Amendment"), which became effective at 4:30 p.m. on June 13, 2025 (the "Effective Time"), to effect a one-for-sixty (1:60) reverse stock split (the "Reverse Stock Split"), of the shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The Reverse Stock Split was approved by the Company's stockholders at the 2025 annual meeting of the stockholders on May 22, 2025.

As a result of the Reverse Stock Split, every 60 shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split. Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the Reverse Stock Split ratio were entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.

Following the Reverse Stock Split, the number of shares of Common Stock outstanding was proportionally reduced from 34,047,337 shares to approximately 567,456 shares. The shares of Common Stock underlying the Company's outstanding stock options and warrants will be similarly adjusted along with corresponding adjustments to their exercise prices.

The Company's transfer agent, VStock Transfer, LLC, is the exchange agent for the Reverse Stock Split and will correspond with stockholders of record regarding the Reverse Stock Split. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split.

The Common Stock will begin trading on a reverse stock split-adjusted basis upon market open on June 16, 2025. The ticker symbol for the Common Stock will remain "GCTK." The new CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q804.

The forgoing description of the Certificate of Amendment does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the Certificate of Amendment which is attached as Exhibit 3.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

**Item 8.01 Other Events**

The table below sets forth the impact of the Reverse Stock Split on the Company's net loss per common share - basic and diluted; weighted average common shares outstanding - basic and diluted; and shares issued and outstanding, for the years ended December 31, 2024 and 2023, and the three months ended March 31, 2025 and 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** |
|  | **PRE SPLIT (1)** | **PRE SPLIT (1)** | **POST SPLIT (1)** | **POST SPLIT (1)** |
|  | **YEAR ENDED DECEMBER 31,** | **YEAR ENDED DECEMBER 31,** | **YEAR ENDED DECEMBER 31,** | **YEAR ENDED DECEMBER 31,** |
|  | **2024** | **2023** | **2024** | **2023** |
| Comprehensive net loss | $22573 | $7098 | $22573 | $7098 |
| Net loss per common share - basic | $68.44 | $34.18 | $4101.94 | $2050.85 |
| Net loss per common share - diluted | $68.44 | $34.18 | $4101.94 | $2050.85 |
| Weighted average common shares outstanding - basic | 330171 | 207603 | 5503 | 3461 |
| Weighted average common shares outstanding - diluted | 330171 | 207603 | 5503 | 3461 |
| Common stock outstanding at year end | 791609 | 208914 | 13194 | 3482 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** | **In thousands of US Dollars**<br> **(except stock and per stock amounts)** |
|  | **PRE SPLIT (2)** | **PRE SPLIT (2)** | **POST SPLIT (2)** | **POST SPLIT (2)** |
|  | **3 MONTHS ENDED MARCH 31,** | **3 MONTHS ENDED MARCH 31,** | **3 MONTHS ENDED MARCH 31,** | **3 MONTHS ENDED MARCH 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Comprehensive net loss | $6797 | $2921 | $6797 | $2921 |
| Net loss per common share - basic | $0.67 | $11.73 | $40.14 | $702.16 |
| Net loss per common share - diluted | $0.67 | $11.73 | $40.14 | $702.16 |
| Weighted average common shares outstanding - basic | 10160725 | 249598 | 169346 | 4160 |
| Weighted average common shares outstanding - diluted | 10160725 | 249598 | 169346 | 4160 |
| Common stock outstanding at period end | 25585853 | 267564 | 426431 | 4460 |

---

(1) The
 pre-split amounts represent the amounts reported in the Company's Form 10-K filed on March 31, 2025. The post-split amounts
 include the effects of the 1 for 60 reverse stock split completed in June 2025.

(2) The
 pre-split amounts represent the amounts reported in the Company's Form 10-Q filed on May 14, 2025. The post-split amounts include
 the effects of the 1 for 60 reverse stock split completed in June 2025.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit <br> No.** | **Description** |
| 3.1 | [Certificate of Amendment to Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on June 13, 2025.](ex3-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 16, 2025 |  |  |
|  | **GLUCOTRACK, INC.** | **GLUCOTRACK, INC.** |
|  | By: | */s/ Paul Goode* |
|  | Name: | Paul Goode |
|  | Title: | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT**

**OF CERTIFICATE OF INCORPORATION**

**OF GLUCOTRACK, INC.**

Glucotrack, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), does hereby certify as follows:

1. The name of the Corporation is Glucotrack, Inc.

2. The Certificate of Incorporation of the Corporation is amended by replacing Article IV with the following:

"The total number of shares of common stock which the Corporation is authorized to issue is 250,000,000 shares, par value $0.001 per share ("Common Stock"), and the total number of shares of preferred stock which the Corporation is authorized to issue is 10,000,000 shares, par value $0.001 per share.

The Board of Directors of the Corporation is hereby expressly authorized to provide, out of the unissued shares of preferred stock, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

Upon the filing and effectiveness (the "Effective Time") of this amendment to the Corporation's Certificate of Incorporation, as amended, pursuant to the Delaware General Corporation Law, each 60 shares of the Common Stock issued immediately prior to the Effective Time (the "Old Common Stock") shall be reclassified and combined into one validly issued, fully paid and non-assessable share of the Corporation's Common Stock, $0.001 par value per share (the "New Common Stock"), without any action by the holder thereof, subject to the treatment of fractional share interests as described below (the "Reverse Stock Split"). No fractional shares of New Common Stock shall be issued as a result of the Reverse Stock Split and, any person who would otherwise be entitled to a fractional share of New Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a whole share of New Common Stock in lieu of any fractional share created as a result of such Reverse Stock Split. Each book entry position that theretofore represented shares of Old Common Stock shall thereafter represent that number of shares of New Common Stock into which the shares of Old Common Stock represented by such book entry position shall have been reclassified and combined; provided, that each person holding of record a book entry position that represented shares of Old Common Stock shall receive, a new book entry position evidencing and representing the number of shares of New Common Stock to which such person is entitled under the foregoing reclassification and combination.

The Reverse Stock Split shall not affect the total number of shares of capital stock, including the Common Stock, that the Corporation is authorized to issue, which shall remain as set forth under this Article IV."

3. This Certificate of Amendment has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.

4. This Certificate of Amendment shall become effective as of 4:30 p.m., Eastern Time on June 13, 2025.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly executed in its corporate name as of the 13<sup>th</sup> day of June, 2025.

---

| | |
|:---|:---|
| **GLUCOTRACK, INC.** | **GLUCOTRACK, INC.** |
| /s/ Paul V. Goode | /s/ Paul V. Goode |
| Name: | Paul V. Goode |
| Title: | Chief Executive Officer |

---